A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
A phase 3 trial of Elinzanetant (BAY3427080) in HR-positive / HER2-negative breast cancer, run by Bayer, active and no longer recruiting.
Overview
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer is a phase 3 interventional study registered as NCT05587296 by Bayer, with 474 participants enrolled, started 2022-10-14 and due to reach its primary completion in 2024-01-29. Interventions recorded: Elinzanetant (BAY3427080) and Placebo. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Shares Bayer and the tag pipeline.
- TrialA Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Shares Bayer and the tag pipeline.
- TrialA Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Shares Bayer and the tag pipeline.
- TrialStudy of TYK-00540 Tablets in Patients With Advanced Solid Tumors
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
Shares Bayer and the tag pipeline.
- TrialA Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
Shares Bayer and the tag pipeline.
- TrialStudy to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Shares Bayer and the tag pipeline.
- TrialA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.